Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE in RelapSed Myeloma Plus rEsponse Adapted Cyclophosphamide as a Tailored InnoVativE Strategy
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PESPECTIVE
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.
- 27 Oct 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Status changed from recruiting to active, no longer recruiting.